Deutsche Bank’s Clovis Oncology, Inc. CLVS Stock Holding History

Deutsche Bank’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-300	Closed	-$16K	–	6147
2014 Q4	$16K	Buy	+300	New	+$15.8K	﹤0.01%	5593

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Deutsche Bank's CLVS Position: Q2 2022 in Review

Deutsche Bank sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 64,477 shares — an estimated $131K sold.

Deutsche Bank first reported a position in CLVS in Q2 2013 and held it in 36 quarters. The position peaked at $28.3M in Q2 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

Deutsche Bank reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
Deutsche Bank sold 64,477 Clovis Oncology, Inc. shares in Q2 2022, an estimated $131K.
Deutsche Bank first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 36 quarters.
Deutsche Bank's Clovis Oncology, Inc. position peaked at $28.3M in Q2 2017.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.